FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736714809> ?p ?o ?g. }

• W2736714809 abstract "2042 Background: Activated TGF-b signaling has been associated with poor survival in several tumors, including glioma. TGF-b inhibitors are expected to improve outcome. Part B of this Phase I trial assessed safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the intermittent treatment with LY2157299 in combination with lomustine. Methods: After evaluating safety of LY2157299 monotherapy in part A of the study, 2 cohorts of patients were treated with LY2157299 at 160 or 300 mg/day with intermittent dosing (each cycle=14 days on followed by 14 days off) in combination with lomustine at standard dose (100 to 130 mg/m 2 every 6 weeks) for ≥2 cycles. Toxicity was assessed using the Common Terminology Criteria for Adverse Events, version 3. Results: Twenty-six patients with glioma (18 WHO Grade IV; 5 Grade III; 3 unspecified grade) were treated with LY2157299 and lomustine (160 mg/day, n=15; 300 mg/day, n=11). There were no dose-limiting toxicities. No clinically meaningful cardiotoxicities were observed. Twenty-one SAEs occurred in 10 patients, all considered to be related to lomustine and none to LY2157299. Of the 26 patients, 7 had thrombocytopenia (27%), and recovery around weeks 4 to 6 was not impacted by the second cycle of LY2157299. Two patients taking 160 mg/day were treated for >6 cycles, with 1 of the 2 patients showing an unconfirmed partial response. At the 300 mg/day dose, no responses were observed; 2 patients were treated for >6 cycles. Co-administration of lomustine did not alter LY2157299 exposure. Observed exposure of LY2157299 increased with dose escalation between the 2 cohorts. On Day 7, the variability estimates (coefficients of variation) of exposure and maximum concentration were slightly higher in presence of lomustine (58%) when compared with LY2157299 alone (47%) and then again reduced on Day 14 (53%). Pharmacodynamic results will be reported at a later date. Conclusions: The 14 days on/14 days off treatment with LY2157299 did not increase the known lomustine toxicity. Given the overall safety profile and antitumor effect, LY2157299 is being investigated in Phase II studies." @default.
• W2736714809 created "2017-07-31" @default.
• W2736714809 creator A5001783218 @default.
• W2736714809 creator A5020397401 @default.
• W2736714809 creator A5033549340 @default.
• W2736714809 creator A5051287778 @default.
• W2736714809 creator A5052765751 @default.
• W2736714809 creator A5053506951 @default.
• W2736714809 creator A5064692327 @default.
• W2736714809 creator A5064766886 @default.
• W2736714809 creator A5071750897 @default.
• W2736714809 creator A5077979726 @default.
• W2736714809 creator A5079422406 @default.
• W2736714809 creator A5080323920 @default.
• W2736714809 creator A5086594299 @default.
• W2736714809 creator A5089832055 @default.
• W2736714809 date "2012-05-20" @default.
• W2736714809 modified "2023-10-18" @default.
• W2736714809 title "The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study." @default.
• W2736714809 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.2042" @default.
• W2736714809 hasPublicationYear "2012" @default.
• W2736714809 type Work @default.
• W2736714809 sameAs 2736714809 @default.
• W2736714809 citedByCount "6" @default.
• W2736714809 countsByYear W27367148092012 @default.
• W2736714809 countsByYear W27367148092013 @default.
• W2736714809 countsByYear W27367148092014 @default.
• W2736714809 crossrefType "journal-article" @default.
• W2736714809 hasAuthorship W2736714809A5001783218 @default.
• W2736714809 hasAuthorship W2736714809A5020397401 @default.
• W2736714809 hasAuthorship W2736714809A5033549340 @default.
• W2736714809 hasAuthorship W2736714809A5051287778 @default.
• W2736714809 hasAuthorship W2736714809A5052765751 @default.
• W2736714809 hasAuthorship W2736714809A5053506951 @default.
• W2736714809 hasAuthorship W2736714809A5064692327 @default.
• W2736714809 hasAuthorship W2736714809A5064766886 @default.
• W2736714809 hasAuthorship W2736714809A5071750897 @default.
• W2736714809 hasAuthorship W2736714809A5077979726 @default.
• W2736714809 hasAuthorship W2736714809A5079422406 @default.
• W2736714809 hasAuthorship W2736714809A5080323920 @default.
• W2736714809 hasAuthorship W2736714809A5086594299 @default.
• W2736714809 hasAuthorship W2736714809A5089832055 @default.
• W2736714809 hasConcept C111113717 @default.
• W2736714809 hasConcept C112705442 @default.
• W2736714809 hasConcept C121332964 @default.
• W2736714809 hasConcept C126322002 @default.
• W2736714809 hasConcept C142424586 @default.
• W2736714809 hasConcept C143998085 @default.
• W2736714809 hasConcept C197934379 @default.
• W2736714809 hasConcept C22979827 @default.
• W2736714809 hasConcept C2776694085 @default.
• W2736714809 hasConcept C2776755627 @default.
• W2736714809 hasConcept C2777288759 @default.
• W2736714809 hasConcept C2777793932 @default.
• W2736714809 hasConcept C2778227246 @default.
• W2736714809 hasConcept C2779429289 @default.
• W2736714809 hasConcept C2779434656 @default.
• W2736714809 hasConcept C29730261 @default.
• W2736714809 hasConcept C502942594 @default.
• W2736714809 hasConcept C71924100 @default.
• W2736714809 hasConcept C87355193 @default.
• W2736714809 hasConcept C90924648 @default.
• W2736714809 hasConcept C98274493 @default.
• W2736714809 hasConceptScore W2736714809C111113717 @default.
• W2736714809 hasConceptScore W2736714809C112705442 @default.
• W2736714809 hasConceptScore W2736714809C121332964 @default.
• W2736714809 hasConceptScore W2736714809C126322002 @default.
• W2736714809 hasConceptScore W2736714809C142424586 @default.
• W2736714809 hasConceptScore W2736714809C143998085 @default.
• W2736714809 hasConceptScore W2736714809C197934379 @default.
• W2736714809 hasConceptScore W2736714809C22979827 @default.
• W2736714809 hasConceptScore W2736714809C2776694085 @default.
• W2736714809 hasConceptScore W2736714809C2776755627 @default.
• W2736714809 hasConceptScore W2736714809C2777288759 @default.
• W2736714809 hasConceptScore W2736714809C2777793932 @default.
• W2736714809 hasConceptScore W2736714809C2778227246 @default.
• W2736714809 hasConceptScore W2736714809C2779429289 @default.
• W2736714809 hasConceptScore W2736714809C2779434656 @default.
• W2736714809 hasConceptScore W2736714809C29730261 @default.
• W2736714809 hasConceptScore W2736714809C502942594 @default.
• W2736714809 hasConceptScore W2736714809C71924100 @default.
• W2736714809 hasConceptScore W2736714809C87355193 @default.
• W2736714809 hasConceptScore W2736714809C90924648 @default.
• W2736714809 hasConceptScore W2736714809C98274493 @default.
• W2736714809 hasLocation W27367148091 @default.
• W2736714809 hasOpenAccess W2736714809 @default.
• W2736714809 hasPrimaryLocation W27367148091 @default.
• W2736714809 hasRelatedWork W1956543993 @default.
• W2736714809 hasRelatedWork W1970888488 @default.
• W2736714809 hasRelatedWork W1974530971 @default.
• W2736714809 hasRelatedWork W2027303624 @default.
• W2736714809 hasRelatedWork W2035302762 @default.
• W2736714809 hasRelatedWork W2045318349 @default.
• W2736714809 hasRelatedWork W2116583846 @default.
• W2736714809 hasRelatedWork W2278109184 @default.
• W2736714809 hasRelatedWork W2284711770 @default.
• W2736714809 hasRelatedWork W2332800771 @default.
• W2736714809 hasRelatedWork W2590023245 @default.
• W2736714809 hasRelatedWork W2590647395 @default.
• W2736714809 hasRelatedWork W2595821835 @default.

• next